Generex Biotechnology Corp. (fka GNBTQ)

[Ann1]

"One of the main technical challenges for vaccines is to improve on the old ways of manufacturing proteins, which are too slow for responding to an epidemic. We need to develop platforms that are predictably safe, so regulatory reviews can happen quickly, and that make it easy for manufacturers to produce doses at low cost on a massive scale. For antivirals, we need an organized system to screen existing treatments and candidate molecules in a swift and standardized manner."

Sounds like we can be of assistance with that challenge.

https://www.nejm.org/doi/full/10.1056/NEJMp2003762?query=RP